by Raynovich Rod | Apr 22, 2025 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
Update-3 …ABBVIE (ABBV) beat with adj. EPS 2.46 earnings and revenues of $13.343B an increase of 4%, but tariff issues lurking,,, I$10M investments will be made in U.S. Strong sales $6.264B of new immunology drugs Rinvoq and Skirizi an increase of 16.6%. EPS...
by Raynovich Rod | Apr 16, 2025 | 2024 Rayno Tools and Diagnostics Portfolio, Macro
Update-2 4/21/25…11a EDT..XBI trying to bounce in mid 70s up 1% at $76 handle. SMID biotech movers: EYPT RYTM RZLT WVE GPCR etc. Update-1 4/17/25–UNH shares crash over 20% on earnings release due to higher medical costs. Unbelievable surprise because this...
by Raynovich Rod | Jan 30, 2025 | 2024 Rayno Tools and Diagnostics Portfolio, 2024-25 Life Science Portfolios
update-2 2/4/25 SUPERNUS gets FDA approval for infusion device. Update-1 JAN 31..2:15 p EST.. BIG movers up 5% two of our large cap picks ABBV on stong immunology revenues and VRTX. up on FDA approval of non-opiate painkiller. SMID trades:IBB and XBI flat but...
by Raynovich Rod | Jan 27, 2025 | 2024 Rayno Tools and Diagnostics Portfolio, 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
Looks Good for Biotech Stocks-Why we are bullish. Technicals and Relative Strength (RSI) are lined up for bullish trades and good momentum. Biopharmaceuticals offer good value and new themes such as obesity and neuroscience. Innovation and M&A will drive SMID caps...
by Raynovich Rod | Jan 13, 2025 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
Update-1 1/14/25…Further Updates from JPM Healthcare will be delayed due to WEB Publishing issues (hacks) and travel plans. 1/15/25…10a EST –Core CPI is 0.2% lower than 0.3% expected so its a GREEN SCREEN Day— RISK ON. JPM Healthcare Conference...
by Raynovich Rod | Nov 7, 2024 | 2024-25 Life Science Portfolios, Clinical Diagnostics and Tools
11:11 am on 11/11/24….SMID rally continues led by ETFs and seasonally XBI up 0.85% to $105 level. STRONG MOVERS: ARKG, ADPT, CRBU, CRMD,CYRX, DNLI, EVH, PACB, VCYT etc SMID Biotech Stocks are Primed for GOOD GAINS With election uncertainty over and a benign...
by Raynovich Rod | Sep 23, 2024 | 2024 Rayno Tools and Diagnostics Portfolio, 2024-25 Life Science Portfolios
Update-1 9/26/24… SMID CAP trading list movers today: ADPT, ARKG, CRMD, PACB,RXRX, TEM, TXG, TWST, with IBB up 1.09%. We will summarize complete list over the weekend. Adaptive Biotechnologies (ADPT), soars 22% on European certification. CorMedix...
by Raynovich Rod | May 2, 2024 | 2024 Rayno Tools and Diagnostics Portfolio, 2024-25 Life Science Portfolios
Update-5 SMIDS are running today. Added NVAX to list. ADPT RXRX XBI are movers. UPDATE-4…AT close…XBI tried to rally back to $90 but closed at $88+. XBI drives SMID biotechs and as you can see it’s a red screen day if you are tracking our spec...
by Raynovich Rod | Feb 26, 2024 | 2024 Rayno Tools and Diagnostics Portfolio, 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio
3/1/24…Still plenty of good biotech trades around as XBI recovers over 3% to $101.53. Big movers today were: ABOS, CRMD, DNLI, GERN, IMTX, SUPN. https://www.nasdaq.com/market-activity/etf/xbi/advanced-charting 2/29 at close ..MOmentum is easing with volatility...
by Raynovich Rod | Feb 5, 2024 | 2024-25 Life Science Portfolios, 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals, Clinical Diagnostics and Tools
Healthcare and Life Science Funds and ETFs Healthcare stocks usually provide a defensive posture to a stock portfolio. SMID biotech stocks have been in a bear market since late 2021 but they are coming back since late 2023. So the weighting of large cap biophharma...
